Collagen ii arthritis

studies have shown that many of the cytokines implicated in the onset and progression of both rheumatoid arthritis (RA) and osteoarthritis (OA) also appear to regulate the remodeling of the normal knee extracellular matrix (ECM) following strenuous exertion [].No product related adverse events were observed during the study.At study conclusion, five individuals in the UC-II cohort reported no pain during or after the stepmill protocol (p = 0.031, within visit) as compared to one subject in the placebo group.No significant change in knee extension was observed in the placebo group at any time.Daily supplementation with 40 mg of UC-II was well tolerated and led to improved knee joint extension in healthy subjects.This randomized, double-blind, placebo-controlled study was conducted in healthy subjects who had no prior history of arthritic disease or joint pain at rest but experienced joint discomfort with physical activity.UC-II contains a patented form of undenatured type II collagen derived from chicken sternum.These are proinflammatory molecules that, in conjunction with TNF-α, IL-6 and IL-1β, result in a localized, and transitory inflammatory-like response that is part of the normal repair process occurring in knee joints, serves to moderate remodeling events [] showed that healthy individuals express up to 27-fold greater concentrations of the anti-inflammatory cytokine IL-10 in blood following a marathon run when compared to IL-10 blood levels at rest.It was also noted that the UC-II group exercised longer before experiencing any initial joint discomfort at day 120 (2.8 ± 0.5 min, p = 0.019), compared to baseline (1.4 ± 0.2 min).Joint function was assessed by changes in degree of knee flexion and knee extension as well as measuring the time to experiencing and recovering from joint pain following strenuous stepmill exertion.Fifty-five subjects who reported knee pain after participating in a standardized stepmill performance test were randomized to receive placebo (n = 28) or the UC-II (40 mg daily, n = 27) product for 120 days.By contrast, no significant changes were seen in the placebo group.

UC-II also demonstrated the potential to lengthen the period of pain free strenuous exertion and alleviate the joint pain that occasionally arises from such activities.When normal chondrocytes undergo strenuous mechanical stimulation under static conditions, their physiology shifts towards ECM breakdown, as indicated by the upregulation of several metalloproteinases (MMPs), such as MMP-13 as well as tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6, and various aggrecanases [].This suggests that IL-4 plays a key role in downregulating remodeling functions, restoring articular cartilage homeostasis, as well as decreasing chondrocyte apoptosis following strenuous mechanical loading [].Previous preclinical and clinical studies support the safety and efficacy of UC-II in modulating joint discomfort in osteoarthritis and rheumatoid arthritis.The secretion of this autocrine molecule not only helps in shifting chondrocyte metabolism towards the synthesis of aggrecan and type II collagen, it also downregulates production of nitric oxide (NO) and various MMPs and aggrecanases [].